Support our researchers developing a new treatment for cancer patients
For many years, the University has been at the leading edge of research on Epstein Barr virus (EBV) and its link to certain cancers. This research has led to the development of a potential new treatment for EBV cancers - a therapeutic vaccine to alert the immune system of patients with an EBV-related cancer to attack the cancer cells. The vaccine could help the 200,000 people diagnosed with an EBV-related cancer each year.
Working with Cancer Research UK, the Birmingham research team of Professor Alan Rickinson, Dr Neil Steven and Dr Graham Taylor (all of the School of Cancer Sciences), have already tested the vaccine in a small number of patients with an EBV-related head and neck cancer. It is currently being tested in larger clinical trials worldwide.
The vaccine is now at a key point in the process to turn it into a medicine. The researchers hope to do this sooner by getting additional scientific data from the trials by using the very latest ‘cutting edge’ techniques and are currently raising funds with Cancer Research UK to do this.
However the researchers need to reach their £40,000 target by the 11 December 2014. Please share the information with friends and colleagues.